Sep 2026· Human Genetics· Vol 145· 0 citations· 63 references
Medicine
TL;DR
This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype analysis of the component of phenotype remaining after the PRS-associated component has been removed.
Abstract
Polygenic risk scores (PRS) quantify the component of disease risk captured by measured additive common variants. Their use as a study design variable, rather than only as a predictive endpoint, broadens their scientific value in human genetics. PRS can define informative extremes of common-variant burden, identify discordance between phenotype and PRS-estimated risk, and facilitate the detection of subgroup-specific or residual mechanisms that may be obscured in conventional case-control analyses. This review outlines four major PRS-informed design strategies: tail sampling based on PRS extremes; discordance sampling based on mismatch between phenotype and PRS-implied risk; conditional and stratified genome-wide association analyses using PRS to adjust for / partition background risk; and residual phenotype analysis of the component of phenotype remaining after the PRS-associated component has been removed. It thus provides a practical framework for sample enrichment, subgroup definition, and calibrated epidemiologic comparison. These designs may be especially informative when integrated with sequencing, multi-omics, longitudinal cohorts, and translationally oriented intervention studies. Their application requires careful attention to data leakage, ancestry-related bias, collider structures, and the limits of interpretation.
This review summarizes the principles of PRS, the main sources of variability between models, and its potential applications in risk stratification and personalized cancer screening and addresses limitations in transferability, the need for calibration, and the currently limited evidence for improvements in hard clinic...
Adéla Mišove, E. Macháčková, Klára Nováková et al.· Klinicka onkologie· 0 citations
The current state of bench-to-bedside translation of polygenic risk scores (PRS) is reviewed and it is shown that quality standards must be established to ensure that the potential of PRS can be effectively translated into routine clinical practice.
Johannes Schumacher, V. Koch, C. Maj et al.· Deutsches Ärzteblatt Interna...· 0 citations
An extended PRS (ePRS) framework for type 2 diabetes (T2D) that incorporates locus-by-locus non-additive effects beyond those captured by additive single-locus PRS or linkage disequilibrium (LD) tagging is developed, with potential for clinical use pending prospective validation.
K. Multerer, P. Atkinson, L. Woods et al.· medRxiv· 0 citations
Investigation of whether varying levels of population stratification adjustment altered PRS portability in three broad ancestry groups in the UK Biobank found that increasing PC adjustment did not produce a consistent trend in portability across ancestry groups or phenotypes, despite modest reductions in the LDSC inter...
A. Harikrishnan, C. M. Kelly· medRxiv· 0 citations
It is suggested that nonlinear machine learning do not uniformly outperform standard PRSs; rather, their relative performance depends jointly on genetic architecture and training sample size.
J. Zhu, A. Baousi, A. P. Morris et al.· medRxiv· 0 citations
It is shown that the published hypercholesterolemia PRS (PGS000936) can effectively stratify risk and identify individuals with a high genetic burden in a real-world German clinical setting, supporting its clinical utility when appropriately calibrated for the local population.
L. Bundalian, A. Velluva, E. Gjermeni et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.